PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?

被引:41
作者
Abraham, Jame [1 ]
机构
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA
关键词
AKT inhibitor; breast cancer; combination therapy; mTOR inhibitor; PI3K inhibitor; I PI3K INHIBITOR; PHOSPHATIDYLINOSITOL; 3-KINASE; PHASE-I; ANTIESTROGEN RESISTANCE; ANTITUMOR-ACTIVITY; ENDOCRINE THERAPY; TRASTUZUMAB; EVEROLIMUS; MUTATIONS; GROWTH;
D O I
10.1586/14737140.2015.961429
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway is common in breast cancer. PI3K pathway activation has been associated with tumor growth and progression, and thus is a promising target for breast cancer therapy. Agents targeting the PI3K pathway can restore sensitivity to standard breast cancer therapies, including endocrine, HER2-targeted agents and chemotherapy, by suppressing PI3K pathway activation, which is central to the development of therapeutic resistance. The combination of endocrine therapy and PI3K pathway (mTOR) inhibition has proven clinical benefit, and novel combination strategies involving PI3K pathway inhibitors and other investigational targeted therapies are now being explored clinically in patients with breast cancer.
引用
收藏
页码:51 / 68
页数:18
相关论文
共 98 条
[1]  
Ahnert JR, 2014, J CLIN ONCOL, V32
[2]   Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer [J].
Anders, Carey K. ;
Carey, Lisa A. .
CLINICAL BREAST CANCER, 2009, 9 :S73-S81
[3]   Tracking and Evaluating Molecular Tumor Markers With Cancer Registry Data: HER2 and Breast Cancer [J].
Anderson, William F. ;
Rosenberg, Philip S. ;
Katki, Hormuzd A. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (05)
[4]   Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial [J].
Andre, Fabrice ;
O'Regan, Ruth ;
Ozguroglu, Mustafa ;
Toi, Masakazu ;
Xu, Binghe ;
Jerusalem, Guy ;
Masuda, Norikazu ;
Wilks, Sharon ;
Arena, Francis ;
Isaacs, Claudine ;
Yap, Yoon-Sim ;
Papai, Zsuzsanna ;
Lang, Istvan ;
Armstrong, Anne ;
Lerzo, Guillermo ;
White, Michelle ;
Shen, Kunwei ;
Litton, Jennifer ;
Chen, David ;
Zhang, Yufen ;
Ali, Shyanne ;
Taran, Tetiana ;
Gianni, Luca .
LANCET ONCOLOGY, 2014, 15 (06) :580-591
[5]   Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer [J].
Andre, Fabrice ;
Bachelot, Thomas ;
Campone, Mario ;
Dalenc, Florence ;
Perez-Garcia, Jose M. ;
Hurvitz, Sara A. ;
Turner, Nicholas ;
Rugo, Hope ;
Smith, John W. ;
Deudon, Stephanie ;
Shi, Michael ;
Zhang, Yong ;
Kay, Andrea ;
Porta, Diana Graus ;
Yovine, Alejandro ;
Baselga, Jose .
CLINICAL CANCER RESEARCH, 2013, 19 (13) :3693-3702
[6]   Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab [J].
Andre, Fabrice ;
Campone, Mario ;
O'Regan, Ruth ;
Manlius, Corinne ;
Massacesi, Cristian ;
Sahmoud, Tarek ;
Mukhopadhyay, Pabak ;
Soria, Jean-Charles ;
Naughton, Michael ;
Hurvitz, Sara A. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (34) :5110-5115
[7]  
[Anonymous], J CLIN ONCOL S
[8]  
[Anonymous], P 105 ANN M AM ASS C
[9]  
[Anonymous], SAN ANT BREAST CANC
[10]  
[Anonymous], 2013, MOL CANC THER